Pharmacological treatment of fibromyalgia

Clinical and Experimental Rheumatology

Volumn 28, Issue 6 SUPPL. 63, 2010, Pages

  Di Franco, M ^a   Iannuccelli, C ^a   Atzeni, F ^b   Cazzola, M ^c   Salaffi, F ^d   Valesini, G ^a   Sarzi Puttini, P ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Unit of Rehabilitation Medicine   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Drug; Fibromyalgia; Non pharmacological therapy

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; CORTICOSTEROID; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; GABAPENTIN; GROWTH HORMONE; HYPNOTIC SEDATIVE AGENT; MAPROTILINE; MILNACIPRAN; MOCLOBEMIDE; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYBATE SODIUM; OXYCODONE; PARACETAMOL; PLACEBO; PRAMIPEXOLE; PREGABALIN; S ADENOSYLMETHIONINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TERGURIDE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT;

BEDTIME DOSAGE; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG WITHDRAWAL; EUROPE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERHIDROSIS; LOW DRUG DOSE; NAUSEA; NONHUMAN; OFF LABEL DRUG USE; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA; DRUG THERAPY; METHODOLOGY;

ANALGESICS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DRUG THERAPY; FIBROMYALGIA; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 79952658682     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. WOLFE F, SMYTHE HA, YUNUS MD: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
2. YUNUS MG: Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain Best Pract Res Clin Rheumatol 2007; 21: 481-97.
3. SARZI-PUTTINI P, ATZENI F, DIANA A, DORIA A, FURLAN R: Increased neural sympathetic activation in fibromyalgia syndrome. Ann N Y Acad Sci 2006; 1069: 109-17.
4. DI FRANCO M, IANNUCCELLI C, VALESINI G: Neuroendocrine immunology of fibromyalgia. Ann N Y Acad Sci 2010; 1193: 84-90.
5. SARZI-PUTTINI P, TORTA R, MARINANGELI et al.: Fibromyalgia syndrome: the pharmacological treatment options. Reumatismo 2008; 60 (Suppl. 1):50-8.
6. SARZI-PUTTINI P, BUSKILA D, CARRABBA M, DORIA A, ATZENIF: Treatment strategy in fibromyalgia syndrome: where are we now? Semin Arthritis Rheum 2008; 37: 353-65.
7. CARVILLE SF, ARENDT-NIELSEN S, BLIDDAL H et al.: EULAR. EULAR evidence- based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67:536-41.
8. DI FRANCO M, IANNUNCELLI C, ALESSANDRI C et al.: Autonomic dysfunction and neuropeptide Y in fibromyalgia. Clin Exp Rheumatol 2009; 27: S75-8.
9. KRANZLER JD, GENDREAU JF, RAO SG: The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull 2002; 36: 165-213.
10. MOCHIZUCKI D: Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol 2004; 19: S15-S19,
11. FIELDS HL, HEINRICHER MM, MASON P: Neurotransmittersinnociceptive modulatory circuits. Annu Rev Neurosa. 1991; 14: 219-45.
12. ARNOLD LM, LU Y, CROFFORD U et al.: A double-blind, multicentre trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974-84.
13. Arnold LM, Rosen A, Pritchett YL et al.: A randomized, double-blind, placebocontrolled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119:5-15. (Pubitemid 41752960)
14. Russell IJ, Mease PJ, Smith TR et al.: Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depres- sive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44.
15. CHAPPELL AS, BRADLEY LA, WILTSE C, DETKE MJ, D'SOUZA DN, SPAETH M: A six-month double-blind, placebo-controlled, randomized trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008;1:91-102.
16. ARNOLD LM, CLAUW D, WANG F, AHL J, GAYNOR PJ, WOHLREICH MM: Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebocontrolled trial. J Rheumatol 2010 Sep 15.
17. Mease PJ, Clauw DJ, Gendreau RM et al.: The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009; 36: 389-409.
18. CLAUW DJ, MEASE P, PALMER RH, GENDREAU RM, WANG Y: Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008; 30: 1988-2004.
19. BRANCO JC, ZACHRISSON O, PERROT S et al.: A European, multicenter, randomized, double-blind, placebo-controlled monotherapy clinical trial of milnacipran in the treatment of fibromyalgia. J Rheumatol 2010; 37: 851-9.
20. KYLE JA, DUGAN BD, TESTERMAN KK: Milnacipran for treatment of fibromyalgia. Ann Pharmacother 2010; 44: 1422-9.
21. MEASE PJ: Futher strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. Am J Med 2009; 122: S44-55.
22. ARNOLD LM, GENDREAU RM, PALMER RH, GENDREAUJF.WANG Y: Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 2745-56.
23. Harvey AT, Rudolph RL, Preskorn SH: Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57: 503-9. (Pubitemid 30257265)
24. ZULSTRA TR, BARENDREGT PJ, VAN DE LAAR MAF: Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial [abstract]. Arthritis Rheum 2002; 46: S105.
25. MAZZA M, MAZZA O, POMPONI M et al.: What is the effect of selective serotonin reuptake inhibitors on temperament and character in patients with fibromyalgia? Compr Psychiatry 2009; 50: 240-4.
26. O'MALLEY PG, BALDEN E, TOMKINS G, SANTORO J, KROENKE K, JACKSON JL: Treatment of fibromyalgia with antidepressant, a meta-analysis. J Gen Intern Med 2000; 15: 659-66.
27. Häuser W, Bernardy K, Uceyler N, Sommer C: Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009; 301: 198-209.
28. GOLDENBERG DL, BURCKHARDT C, CROFFORD L: Management of fibromyalgia syndrome. JAMA 2004; 292: 2388-95.
29. MEASE P: Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005; 75: 6-20.
30. CARVILLE SF, ARENDT-NIELSEN S, BLIDDAL H et al. EULAR: EULAR evidence-based recommendations for the management of fibromyalgia syndrome Ann Rheum Dis 2008; 67: 536-41.
31. Bennett RM, Schein J, Kosinski Mr Hewitt DJ, Jordan DM, Rosenthal NR: Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005;53:519-27. (Pubitemid 41278916)
32. BENNETT RM, KAMIN M, KARIM R, ROSENTHAL N: Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003; 114: 537-45.
33. LEPPERT W: Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep 2010, 62: 578-91.
34. Dworkin RH, Backonja M, Rowbotham MC et al.: Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60: 1524-34. (Pubitemid 37443116)
35. SPAETH M: Is pregabalin a safe and effective treatment for patients with fibromyalgia? Nat Clin Pract Rheumatol 2008; 4: 514.
36. Urban MO, Ren K, Park KT et al.: Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. J Pharmacol Exp Ther 2005; 313: 1209-16. (Pubitemid 40727024)
37. PAN HL.EISENACH JC,CHEN SR: Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 1999; 288: 1026-30.
38. HAO JX, XU XJ, URBAN L, WIESENFELD-HALLIN Z: Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats. Neurosci Lett 2000; 280: 211-4.
39. Taylor CP, Gee NS, Su TZ et al.: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 23349.
40. Fink K, Dooley DJ, Meder WP et al.: Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42: 229-36. (Pubitemid 34137026)
41. TAYLOR CP: The biology and pharmacology of calcium channel alpha2-delta proteins Pfizer Satellite Symposium to the 2003 Society for Neuroscience Meeting. CNS Drug Rev 2004; 10: 183-8.
42. VRANKEN JH, DIJKGRAAF MG, KRUIS MR, VAN DER VEGT MH, HOLLMANN MW, HEESEN M: Pregabalin in patients with central neuropathic pain: a randomized, doubleblind, placebo-controlled trial of a flexibledose regimen. Pain 2008; 136: 150-7.
43. RINTALA DH, HOLMES SA, COURTADE D, FIESS RN, TASTARD LV, LOUBSER PG: Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007; 88: 1547-60.
44. KATZ N, BENOIT C: Opioids for neuropathic pain. Curr Pain Headache Rep 2005; 9: 153-60.
45. Häuser W, Bernardy K, Uçeyler N, Sommer C: Treatment of fibromyalgia syndrome with gabapentin and pregabalin - a meta-analysis of randomized controlled trials. Pain 2009; 145: 69-8.
46. SERRA E: Duloxetine and pregabalin: safe and effective for the long-term treatment of fibromyalgia? Nat Clin Pract Neurol 2008; 4: 594-5.
47. HOLMAN AJ, MYERS RR: A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005; 52: 2495-505.
48. SKRABEK RQ, GALIMOVA L, ETHANS K, PERRY D: Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9: 164-73.
49. WARE MA, FTTZCHARLES MA, JOSEPH L, SHIR Y: The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110: 604-10.
50. YOUNGER J. MACKEYS: Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 2009; 10: 663-72.
51. DISTLER O, EICH W, DOKOUPILOVA E et al.: Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multi evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Arthritis Rheum. 2010; 62: 291-300.
52. SCHARF MB, HAUCK M, STOVER R, MCDANNOLD M, BERKOWITZ D: Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J Rheumatol 1998; 25: 1986-90.
53. RUSSELL IJ, PERKINS AT, MICHALEK JE: Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial; Oxybate SXB-26 Fibromyalgia Syndrome Study Group. Arthritis Rheum 2009; 60: 299-309.
54. SCHARF MB, BAUMANN M, BERKOWITZ DV: The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003; 30: 1070-4.
55. MOLDOFSKY H, INHABER NH, GUINTA DR, ALVAREZ-HORINE SB: Effects of sodium oxybate on sleep physiology and sleep/wakerelated symptoms in patients with fibromy-algia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 2010; 37: 2156-66.
56. RUSSEL IJ, FLETCHER EM, MICHALEK JE, MCBROOM PC, HESTER GG: Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A doubleblind, placebo-controlled study. Arthritis Rheum 1991;34:552-60.
57. QUIJADA-CARRERA J, VALENZUELA-CASTAÑO A, POVEDANO-GÓMEZ J et al.: Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain 1996;65:221-5.
58. Giesecke T, Williams DA, Harris RE et al.: Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003; 48: 2916-22. (Pubitemid 37280621)